within Pharmacolibrary.Drugs.ATC.D;

model D07AB11
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00025,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.04,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D07AB11</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Hydrocortisone buteprate is a synthetic corticosteroid used topically for its anti-inflammatory, antipruritic, and vasoconstrictive effects in the treatment of various skin disorders, such as eczema and dermatitis. It is a prescription medication and approved for dermatological use in several countries.</p><h4>Pharmacokinetics</h4><p>No human pharmacokinetic (PK) studies specifically for hydrocortisone buteprate have been published. Its PK parameters are not available in clinical literature; estimates could be made based on systemic corticosteroid absorption through skin, but topical steroids are intended for minimal systemic absorption.</p><h4>References</h4><ol><li><p>Yanagawa, A, Mizushima, Y, Komatsu, A, Horiuchi, M, Shirasawa, E, &amp; Igarashi, R (1987). Application of a drug delivery system to a steroidal ophthalmic preparation with lipid microspheres. <i>Journal of microencapsulation</i> 4(4) 329–331. DOI:<a href=\"https://doi.org/10.3109/02652048709021825\">10.3109/02652048709021825</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3504514/\">https://pubmed.ncbi.nlm.nih.gov/3504514</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D07AB11;
